Limula Confirms Global Protection of IP Portfolio with U.S. Patent Granted

U.S. Patent Certificate issued by the United States Patent and Trademark Office to Limula.

• U.S. Patent strengthens Limula’s IP position and confirms differentiation of its integrated, closed and automated manufacturing technology.
• Technology enables treatment production from patient-derived cells, in a single device, supporting process intensification and decentralisation.
• Limula is inviting industry and clinical partners to join its early access program.

Lausanne, Switzerland, May 6, 2025 – Limula has announced the granting of its key U.S. patent, confirming the company’s leadership in next-generation cell and gene therapy (CGT) manufacturing technologies. The newly granted patent adds to Limula’s growing international IP portfolio, with protection already secured in all other major markets.

The patent covers core innovations in an highly-differentiated platform designed to automate and streamline the production of cell therapies in a single device. Notably, it protects the system’s unique way to integrate multiple functionalities — including cell incubation and cell processing — into a single, closed, and programmable device. This ability to cover all unit operations without transferring cells between modules eliminates the need for multiple tools, reducing footprint, consumable costs and human manual interventions, paving the way for point-of-care manufacturing in hospital settings.

“The IP protection strengthens Limula’s competitive position as we anticipate product launch and continue to engage with hospitals, biotechs, CDMOs, and pharmaceutical partners worldwide in our early access program,” said Luc Henry, CEO and co-founder of Limula. “This patent is a key milestone in our broader strategy to protect the core innovations behind our platform. We will continue to build our IP portfolio as we progress towards making these personalized treatments scalable and accessible to more patients.”

With product development advancing fast, Limula is actively seeking partners interested in testing its technology in its early access program.

To learn more, visit www.limula.ch or contact: [email protected].

About Limula

Limula SA is a life science platform technology company based in Lausanne, Switzerland, dedicated to transforming the manufacturing of Cell & Gene Therapies. Their mission is to accelerate the development and commercialisation of new advanced therapies through an automated, on-demand, and scalable manufacturing solution. Limula’s proprietary platform integrates all functionalities into a single device, empowering therapeutics developers to bring life-saving treatments to patients more efficiently.

Contact Details

Luc Henry, DPhil
[email protected]
www.limula.ch